Empagliflozin in Patients with Chronic Kidney Disease

Drs. Neuen and Heerspink report serving as Secretariat of the SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists Consortium. Dr. Neuen reports having received fees for travel support, advisory boards, and steering committee roles from AstraZeneca, Bayer, Boehringer Ingelhim, and Janssen, with all honoraria paid to his institution. Dr. Heerspink reports being a consultant for AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL Pharma, Gilead, Janssen, Merck, Mitsubishi Tanabe, Mundi Pharma, Novo Nordisk, and Travere. No other potential conflict of interest relevant to this letter was reported.